Metodebevisregistrering

Dose-Escalation Design

Dose-Escalation Design, formalized as the Continual Reassessment Method (CRM), is a Bayesian adaptive algorithm for identifying the Maximum Tolerated Dose (MTD) in Phase I clinical trials. Introduced by John O'Quigley, Margaret Pepe, and Lloyd Fisher in 1990, CRM treats dose-toxicity response as a parametric curve, updates a prior probability model after each patient's outcome, and assigns subsequent patients to the dose currently estimated closest to a pre-specified target toxicity probability.

Sources recorded, not reviewed

Kilderegistrering

Citater kopieret ordret fra metodens kilderegistrering. Ingen påstandsniveauverifikation er udledt heraf.

Dose-Escalation Design (Continual Reassessment Method)

Taksonomisk metoderegistrering · process-pipeline / experimental-design

O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. · DOI 10.2307/2531628

Åbn fuld metode

Kuraterede påstande

Påstande gemt i bevis-loggen, hver med sin egen vurdering.

Ingen kuraterede påstande endnu

Denne visning opfinder ikke en påstandsvurdering, når loggen ingen har.

Relaterede metoder

Genereret fra metodegrafen og vist som maskinelt foreslåede relationer — ingen bevispåstand er udledt.